POMALYST® (pomalidomide) homepage

This site is intended for US audiences only.

POMALYST is a prescription medicine, taken along with the medicine dexamethasone, used to treat adults with multiple myeloma who have previously received at least 2 medicines to treat multiple myeloma, including a proteasome inhibitor and lenalidomide, and whose disease has become worse during treatment or within 60 days of finishing the last treatment. It is not known if POMALYST is safe and effective in children.

The REMS Companion App

Easily access the POMALYST REMS® program.

Download now

POMALYST with dexamethasone is proven to continue the fight.

If your multiple myeloma (MM) stops responding to REVLIMID® (lenalidomide) and a proteasome inhibitor (PI), see if a regimen containing POMALYST could be the next step in your treatment journey.

It’s a pill that offers convenient once-daily dosing.*

It’s been used to treat more than 72,000 patients with
relapsed MM.†‡

Pomalidomide (POMALYST) is part of a treatment regimen that’s recommended by the National Comprehensive Cancer Network® (NCCN®).§1

Hypothetical doctor talking to a hypothetical POMALYST® (pomalidomide) patient with relapsed/refractory multiple myeloma while showing them their laptop
Hypothetical doctor talking to a hypothetical POMALYST® (pomalidomide) patient with relapsed/refractory multiple myeloma while showing them their laptop

Not an actual patient.

Start the conversation with
your doctor.

When relapse happens, make sure you talk with your doctor
about treatment options. Use our Why POMALYST? guide to
help get the conversation started.

get the guide

*Taken on Days 1-21 out of a 28-day cycle or as directed by your doctor.

According to POMALYST Risk Evaluation and Mitigation Strategy (REMS) Program enrollments from February 2013-February 2023.

POMALYST may not work for everyone. Ask your doctor if POMALYST with dexamethasone is right for you. Individual results may vary.

§As part of a combination therapy for appropriate patients after one prior therapy including lenalidomide and a PI.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

HOW POMALYST WORKS

Taken in combination with dexamethasone, POMALYST
was shown to work in 3 ways in animal models and in vitro*:

STIMULATE

Helps enhance the function of certain cells used by the immune system to fight myeloma.

STRIKE

Targets and kills myeloma cells, even those resistant to REVLIMID.

STARVE

Helps reduce new myeloma cell growth by limiting blood supply.

*In vitro: in a test tube or glass; outside of a living organism.

A clinical trial proved POMALYST with dexamethasone was effective in patients with relapsed/refractory multiple myeloma.

Based on results of a clinical trial, the FDA has approved the use of POMALYST with low-dose dexamethasone.

A clinical trial studied 455 patients whose multiple myeloma had stopped responding to at least 2 prior medicines, including REVLIMID and a PI. A total of 302 patients received POMALYST with low-dose dexamethasone, and 153 patients received high-dose dexamethasone alone.

The phase 3 clinical trial was designed to determine if POMALYST with low-dose dexamethasone could be an effective treatment for relapsed multiple myeloma.

MEDIAN OVERALL SURVIVAL (OS) RESULTS

Median Overall Survival: Think of median as the middle value of a set of data points. Overall survival measures the amount of time patients were alive following the start of the trial.

Median overall survival results for POMALYST® (pomalidomide) with low-dose dexamethasone vs high-dose dexamethasone alone Median overall survival results for POMALYST® (pomalidomide) with low-dose dexamethasone vs high-dose dexamethasone alone

Study findings: Median OS for patients taking POMALYST with low-dose dexamethasone was 12.4 months. This is roughly 1.5 times longer than the 8 months that patients lived when they were given high-dose dexamethasone alone.

MEDIAN PROGRESSION-FREE SURVIVAL (PFS) RESULTS

Median Progression-Free Survival: Progression-free survival measures how long a patient lives without the disease getting worse. The main goal of the study was to measure median PFS.

Median progression-free survival results for POMALYST® (pomalidomide) with low-dose dexamethasone vs high-dose dexamethasone alone Median progression-free survival results for POMALYST® (pomalidomide) with low-dose dexamethasone vs high-dose dexamethasone alone

Study findings: Median PFS for patients taking POMALYST with low-dose dexamethasone was 3.6 months. This was 2 times longer than the 1.8 months that patients lived without their disease getting worse when they were given high-dose dexamethasone alone.

POMALYST may not work for everyone. Ask your doctor if POMALYST with dexamethasone is right for you. Individual results may vary.

Safety findings: Common side effects of POMALYST (≥30%) include low white blood cells, low red blood cells, tiredness and weakness, upper respiratory tract infection, low platelets, fever, shortness of breath, diarrhea, constipation, back pain, and nausea.

RRMM COMBINATION THERAPIES

POMALYST is used in several FDA-approved combinations
with dexamethasone, for patients who have received prior treatments that included REVLIMID and a PI.*2

Your doctor may discuss these other treatment options with you and the associated risks and benefits. Please see the Combinations page to learn more about relapsed multiple myeloma treatment options.

LEARN MORE

*Please see full Prescribing Information, including Boxed WARNINGS, for REVLIMID.

POMALYST may not work for everyone. Ask your doctor if POMALYST with dexamethasone is right for you. Individual results may vary.

Before taking POMALYST, you need to join the POMALYST REMS® program.

LEARN MORE

Get a comprehensive guide to POMALYST with the Treatment Overview Brochure.

Download

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.3.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed May 10, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. 2. Pomalidomide [package insert]. Summit, NJ: Celgene Corp; 2022.

Important dosing information

  • Take POMALYST exactly as prescribed, and follow all the instructions of the POMALYST REMS® program.
  • Swallow POMALYST capsules whole with water 1 time a day. Do not break, chew, or open your capsules.
  • POMALYST may be taken with or without food.
  • Take POMALYST at about the same time each day.
  • If you are on hemodialysis, take POMALYST after hemodialysis, on hemodialysis days.
  • Do not open the POMALYST capsules or handle them any more than needed. If you touch a broken POMALYST capsule or the medicine in the capsule, wash the area of your body right away with soap and water.
  • If you miss a dose of POMALYST and it has been less than 12 hours since your regular time, take it as soon as you remember. If it has been more than 12 hours, just skip your missed dose.
  • Do not take 2 doses at the same time.
  • If you take too much POMALYST, call your healthcare provider right away.
  • Do not share POMALYST with other people. It may cause birth defects and other serious problems.

POMALYST is a
once-daily capsule.*
See how to take it.

VIEW DOSING

*POMALYST is taken once a day on days 1-21
of a 28-day cycle.

 POMALYST is taken in combination with
dexamethasone.

POMALYST is a
once-daily capsule.*
See how to take it.

VIEW DOSING

*POMALYST is taken once a day on days 1-21
of a 28-day cycle.

 POMALYST is taken in combination with
dexamethasone.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.